Keywords
Ocrelizumab
Anti-CD20 therapy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the efficacy and safety of ocrelizumab in the treatment of multiple sclerosis, considering its effects on relapses, disability progression, radiological activity and adverse events. Methods: This is an integrative literature review with a descriptive design and qualitative approach, conducted in PubMed, Virtual Health Library and Cochrane Library databases. The guiding question was structured according to the PICO strategy, including adult patients with relapsing-remitting or primary progressive multiple sclerosis, treatment with ocrelizumab, comparison with placebo, interferon beta-1a, standard dose or alternative strategies, and clinical, radiological and safety outcomes. Articles published between 2017 and 2026 were included, resulting in a final sample of 14 studies. Results: Ocrelizumab was associated with reduced relapse rates, disability progression and inflammatory activity on magnetic resonance imaging. The standard 600 mg regimen was effective, whereas higher doses did not show relevant additional clinical benefit. The most frequent adverse events were infusion-related reactions and infections, usually mild to moderate in severity. Final considerations: Ocrelizumab is an effective and safe therapy for multiple sclerosis, with promising perspectives involving subcutaneous formulations, biosimilars and individualized treatment strategies.
References
ARNOLD DL, et al. Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal, 2025.
CERQUEIRA JJ, et al. Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension. Neurology, 2025; 104(4): e210142.
DIMAURO KA, et al. Management of multiple sclerosis in older adults: review of current evidence and future perspectives. Journal of Neurology, 2024.
FILIPPINI G, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database of Systematic Reviews, 2017.
FOX EJ, et al. Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal, 2018; 24(14): 1862–1870.
GIOVANNONI G, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet, 2026; 407(10544): 2195–2207.
GRAF J, et al. Updated Multiple Sclerosis Incidence, 2015-2022. JAMA Neurology, 2024; 81(10): 1100.
HARTUNG H-P, et al. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial. Journal of Neurology, 2024.
HAUSER SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017; 376(3): 221–234.
HAUSER SL, et al. Efficacy and safety of a bodyweight–adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. The Lancet, 2026; 407(10544): 2180–2194.
LAMB YN. Ocrelizumab: A Review in Multiple Sclerosis. Drugs, 2022; 82(3): 323–334.
LIN M, et al. Ocrelizumab for multiple sclerosis. The Cochrane Database of Systematic Reviews, 2022; 5: CD013247.
MAYER L, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Multiple Sclerosis and Related Disorders, 2019; 30: 236–243.
MONTALBAN X, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017; 376(3): 209–220.
NEWSOME SD, et al. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis. Neurology, 2025; 104(9).
SAGUIL A, et al. Multiple Sclerosis: A Primary Care Perspective. American Family Physician, 2022; 106(2): 173–183.
SAHRAIAN MA, et al. Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial. Scientific Reports, 2024; 14(1).
SOUZA MT, et al. Revisão integrativa: o que é e como fazer. Einstein, 2010; 8(1): 102–108.
TURNER B, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology, 2019; 266(5): 1182–1193.
WOLINSKY JS, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. The Lancet Neurology, 2020.
ZIVADINOV R, et al. Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study. Journal of Neurology, Neurosurgery & Psychiatry, 2024; 95(6): 536–543.